Literature DB >> 8034704

Monomeric activin A retains high receptor binding affinity but exhibits low biological activity.

P Hüsken-Hindi1, K Tsuchida, M Park, A Z Corrigan, J M Vaughan, W W Vale, W H Fischer.   

Abstract

Activins are multipotent hormones/growth factors that belong to the transforming growth factor-beta (TGF-beta) superfamily. Like TGF-beta s, activins have 9 conserved cysteine residues and are disulfide-bonded dimers. Based on the three-dimensional structure of TGF-beta 2, we deduced Cys80 in activin A to form the intermolecular disulfide bond. To obtain a monomeric form of activin, Cys80 was exchanged for a serine residue by polymerase chain reaction mutagenesis. The mutant protein was expressed in a baculovirus/insect cell expression system. The molecular mass of this mutant activin was determined to be 13 kDa (consistent with a single chain form of the protein) by SDS-polyacrylamide gel electrophoresis and by laser desorption mass spectroscopy. When this mutant monomeric activin was incubated with cells that expressed either the activin type IIB receptor or both the type I and type IIB receptors, its affinity was found to be 20% of that of native activin on a mass basis. Binding affinity determined using the mouse pituitary cell line AtT 20 was 10% of that of native activin A. Biological potency, however, as determined by the mutant protein's ability to release FSH from anterior pituitary cells in primary culture and by its ability to suppress basal ACTH secretion form AtT 20 cells, was only 1% of that of the native protein. This discrepancy of an order of magnitude between binding and biological activity is consistent with a model in which dimerization of the hormone is not necessary for high affinity binding to its receptor(s) while being essential for efficient signal transduction.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8034704

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  Activin A binds to perlecan through its pro-region that has heparin/heparan sulfate binding activity.

Authors:  Shaoliang Li; Chisei Shimono; Naoko Norioka; Itsuko Nakano; Tetsuo Okubo; Yoshiko Yagi; Maria Hayashi; Yuya Sato; Hitomi Fujisaki; Shunji Hattori; Nobuo Sugiura; Koji Kimata; Kiyotoshi Sekiguchi
Journal:  J Biol Chem       Date:  2010-09-15       Impact factor: 5.157

2.  The crystal structure of TGF-beta 3 and comparison to TGF-beta 2: implications for receptor binding.

Authors:  P R Mittl; J P Priestle; D A Cox; G McMaster; N Cerletti; M G Grütter
Journal:  Protein Sci       Date:  1996-07       Impact factor: 6.725

3.  Activins and follistatins: Emerging roles in liver physiology and cancer.

Authors:  Emanuel Kreidl; Deniz Oztürk; Thomas Metzner; Walter Berger; Michael Grusch
Journal:  World J Hepatol       Date:  2009-10-31

4.  Members of the DAN family are BMP antagonists that form highly stable noncovalent dimers.

Authors:  Chandramohan Kattamuri; David M Luedeke; Kristof Nolan; Scott A Rankin; Kenneth D Greis; Aaron M Zorn; Thomas B Thompson
Journal:  J Mol Biol       Date:  2012-10-09       Impact factor: 5.469

5.  Reconstitution of a pentameric complex of dimeric transforming growth factor beta ligand and a type I, II, III receptor in baculoviral-infected insect cells.

Authors:  K Matsuzaki; M Kan; W L McKeehan
Journal:  In Vitro Cell Dev Biol Anim       Date:  1996-06       Impact factor: 2.416

6.  TGF-beta superfamily members promote survival of midbrain dopaminergic neurons and protect them against MPP+ toxicity.

Authors:  K Krieglstein; C Suter-Crazzolara; W H Fischer; K Unsicker
Journal:  EMBO J       Date:  1995-02-15       Impact factor: 11.598

Review 7.  Activin, neutrophils, and inflammation: just coincidence?

Authors:  Paschalis Sideras; Eirini Apostolou; Athanasios Stavropoulos; Alexandros Sountoulidis; Arianna Gavriil; Anastasia Apostolidou; Evangelos Andreakos
Journal:  Semin Immunopathol       Date:  2013-02-06       Impact factor: 9.623

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.